Clinically localised prostate cancer is microsatellite stable.

OBJECTIVES: To determine the frequency of microsatellite instability (MSI) change with mono-, di- and tetranucleotide markers in clinically localized prostate cancer, and to correlate those markers with clinical and pathological variables. MATERIALS AND METHODS: Two forms of MSI have been described...

ver descrição completa

Detalhes bibliográficos
Principais autores: Azzouzi, A, Catto, J, Rehman, I, Larre, S, Roupret, M, Feeley, K, Cussenot, O, Meuth, M, Hamdy, F
Formato: Journal article
Idioma:English
Publicado em: 2007
_version_ 1826304385048641536
author Azzouzi, A
Catto, J
Rehman, I
Larre, S
Roupret, M
Feeley, K
Cussenot, O
Meuth, M
Hamdy, F
author_facet Azzouzi, A
Catto, J
Rehman, I
Larre, S
Roupret, M
Feeley, K
Cussenot, O
Meuth, M
Hamdy, F
author_sort Azzouzi, A
collection OXFORD
description OBJECTIVES: To determine the frequency of microsatellite instability (MSI) change with mono-, di- and tetranucleotide markers in clinically localized prostate cancer, and to correlate those markers with clinical and pathological variables. MATERIALS AND METHODS: Two forms of MSI have been described in human cancer: MSI typical of hereditary nonpolyposis colon cancer, defined with mono- and dinucleotide repeat MS; and a second variety of MSI is best seen at selective tetranucleotide repeats, i.e. elevated microsatellite alterations at select tetranucleotides (EMAST). Prostate specimens were taken from 50 patients. The MS analysis used the Bethesda consensus panel (BCP) and four tetranucleotide loci shown to detect the presence of EMAST. RESULTS: All but four tumours were stable for the 14 loci investigated. There were two (4%) cases with adenomatous polyposis coli (APC) instability among the BCP markers and the same instability rate (4%) amongst the EMAST markers. These four tumours were all unstable at one locus of the 10 markers of the BCP that classified them as MS stable. CONCLUSIONS: The MSI related to a mismatch repair deficiency or to the EMAST does not seem to be important in prostate cancer in the early stages of the disease.
first_indexed 2024-03-07T06:17:00Z
format Journal article
id oxford-uuid:f16aa2e4-8da1-4e7d-bf03-d6ca2db234b3
institution University of Oxford
language English
last_indexed 2024-03-07T06:17:00Z
publishDate 2007
record_format dspace
spelling oxford-uuid:f16aa2e4-8da1-4e7d-bf03-d6ca2db234b32022-03-27T11:56:00ZClinically localised prostate cancer is microsatellite stable.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f16aa2e4-8da1-4e7d-bf03-d6ca2db234b3EnglishSymplectic Elements at Oxford2007Azzouzi, ACatto, JRehman, ILarre, SRoupret, MFeeley, KCussenot, OMeuth, MHamdy, F OBJECTIVES: To determine the frequency of microsatellite instability (MSI) change with mono-, di- and tetranucleotide markers in clinically localized prostate cancer, and to correlate those markers with clinical and pathological variables. MATERIALS AND METHODS: Two forms of MSI have been described in human cancer: MSI typical of hereditary nonpolyposis colon cancer, defined with mono- and dinucleotide repeat MS; and a second variety of MSI is best seen at selective tetranucleotide repeats, i.e. elevated microsatellite alterations at select tetranucleotides (EMAST). Prostate specimens were taken from 50 patients. The MS analysis used the Bethesda consensus panel (BCP) and four tetranucleotide loci shown to detect the presence of EMAST. RESULTS: All but four tumours were stable for the 14 loci investigated. There were two (4%) cases with adenomatous polyposis coli (APC) instability among the BCP markers and the same instability rate (4%) amongst the EMAST markers. These four tumours were all unstable at one locus of the 10 markers of the BCP that classified them as MS stable. CONCLUSIONS: The MSI related to a mismatch repair deficiency or to the EMAST does not seem to be important in prostate cancer in the early stages of the disease.
spellingShingle Azzouzi, A
Catto, J
Rehman, I
Larre, S
Roupret, M
Feeley, K
Cussenot, O
Meuth, M
Hamdy, F
Clinically localised prostate cancer is microsatellite stable.
title Clinically localised prostate cancer is microsatellite stable.
title_full Clinically localised prostate cancer is microsatellite stable.
title_fullStr Clinically localised prostate cancer is microsatellite stable.
title_full_unstemmed Clinically localised prostate cancer is microsatellite stable.
title_short Clinically localised prostate cancer is microsatellite stable.
title_sort clinically localised prostate cancer is microsatellite stable
work_keys_str_mv AT azzouzia clinicallylocalisedprostatecancerismicrosatellitestable
AT cattoj clinicallylocalisedprostatecancerismicrosatellitestable
AT rehmani clinicallylocalisedprostatecancerismicrosatellitestable
AT larres clinicallylocalisedprostatecancerismicrosatellitestable
AT roupretm clinicallylocalisedprostatecancerismicrosatellitestable
AT feeleyk clinicallylocalisedprostatecancerismicrosatellitestable
AT cussenoto clinicallylocalisedprostatecancerismicrosatellitestable
AT meuthm clinicallylocalisedprostatecancerismicrosatellitestable
AT hamdyf clinicallylocalisedprostatecancerismicrosatellitestable